Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Peptides
|
March 7, 2006
Immunogenicity of xenopeptide hormone therapies
Catherine A Schnabel, S Edwin Fineberg, Dennis D Kim
American Journal of Hypertension
|
May 7, 2002
Effects of age, race, gender, blood pressure, and estrogen on arterial compliance
Myron H Weinberger, Naomi S Fineberg, S Edwin Fineberg
American Journal of Hypertension
|
August 6, 2002
The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans
Myron H Weinberger, Naomi S Fineberg, S Edwin Fineberg
Diabetes Technology & Therapeutics
|
July 10, 2007
Insulin antibodies with pulmonary delivery of insulin
S Edwin Fineberg, Thomas T Kawabata, Alan S Krasner, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 3, 2005
Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial
S Edwin Fineberg, Tom Kawabata, Deborah Finco-Kent, et al.
Journal of Clinical Epidemiology
|
February 28, 2002
Long-term follow-up of participants in clinical studies
Morris Weinberger, Myron H Weinberger, Naomi Fineberg, et al.
Diabetes Care
|
December 28, 2002
Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes
S Edwin Fineberg, Jie Huang, Rocco Brunelle, et al.
Diabetes Care
|
July 30, 2002
Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters
Madelyn L Wheeler, S Edwin Fineberg, Naomi S Fineberg, et al.
Endocrine Reviews
|
September 6, 2007
Immunological responses to exogenous insulin
S Edwin Fineberg, Thomas T Kawabata, Deborah Finco-Kent, et al.
Current Medical Research and Opinion
|
October 3, 2008
Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy
William T Cefalu, Nancy J V Bohannon, S Edwin Fineberg, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Peptides
|
March 7, 2006
Immunogenicity of xenopeptide hormone therapies
Catherine A Schnabel, S Edwin Fineberg, Dennis D Kim
American Journal of Hypertension
|
May 7, 2002
Effects of age, race, gender, blood pressure, and estrogen on arterial compliance
Myron H Weinberger, Naomi S Fineberg, S Edwin Fineberg
American Journal of Hypertension
|
August 6, 2002
The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans
Myron H Weinberger, Naomi S Fineberg, S Edwin Fineberg
Diabetes Technology & Therapeutics
|
July 10, 2007
Insulin antibodies with pulmonary delivery of insulin
S Edwin Fineberg, Thomas T Kawabata, Alan S Krasner, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 3, 2005
Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial
S Edwin Fineberg, Tom Kawabata, Deborah Finco-Kent, et al.
Journal of Clinical Epidemiology
|
February 28, 2002
Long-term follow-up of participants in clinical studies
Morris Weinberger, Myron H Weinberger, Naomi Fineberg, et al.
Diabetes Care
|
December 28, 2002
Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes
S Edwin Fineberg, Jie Huang, Rocco Brunelle, et al.
Diabetes Care
|
July 30, 2002
Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters
Madelyn L Wheeler, S Edwin Fineberg, Naomi S Fineberg, et al.
Endocrine Reviews
|
September 6, 2007
Immunological responses to exogenous insulin
S Edwin Fineberg, Thomas T Kawabata, Deborah Finco-Kent, et al.
Current Medical Research and Opinion
|
October 3, 2008
Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy
William T Cefalu, Nancy J V Bohannon, S Edwin Fineberg, et al.
Page
of 1